Atlas Venture Life Science Advisors’s Viridian Therapeutics VRDN Stock Holding History

Atlas Venture Life Science Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-90,072	Closed	-$2.29M	–	16
2023 Q1	$2.29M	Hold	90,072	–	–	0.31%	15
2022 Q4	$2.63M	Hold	90,072	–	–	0.32%	15
2022 Q3	$1.85M	Hold	90,072	–	–	0.2%	17
2022 Q2	$1.04M	Hold	90,072	–	–	0.17%	15
2022 Q1	$1.67M	Hold	90,072	–	–	0.21%	16
2021 Q4	$1.78M	Buy	+90,072	New	+$1.68M	0.16%	16

Other funds holding VRDN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Atlas Venture Life Science Advisors's VRDN Position: Q2 2023 in Review

Atlas Venture Life Science Advisors sold out of Viridian Therapeutics (VRDN) in Q2 2023, closing a stake of 90,072 shares — an estimated $2.29M sold.

Atlas Venture Life Science Advisors first reported a position in VRDN in Q4 2021 and held it in 6 quarters. The position peaked at $2.63M in Q4 2022. 128 funds tracked by Wall St. Rank hold VRDN as of Q2 2023.

Atlas Venture Life Science Advisors reported no remaining Viridian Therapeutics position as of Q2 2023 after selling out during the quarter.
Atlas Venture Life Science Advisors sold 90,072 Viridian Therapeutics shares in Q2 2023, an estimated $2.29M.
Atlas Venture Life Science Advisors first reported a position in Viridian Therapeutics in Q4 2021 and held it in 6 quarters.
Atlas Venture Life Science Advisors's Viridian Therapeutics position peaked at $2.63M in Q4 2022.
128 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2023.

Based on Atlas Venture Life Science Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.